PAYSPaySign, Inc.

The updated analyst work on Paysign now points to a higher implied fair value, with the modeled figure moving from US$10.45 to US$13.10. Bullish analysts link these higher targets to a stronger reaction to Paysign’s recent Q2 report, raised guidance and growing confidence in the company’s execution, including new pharma program wins. As you read on, you will see how these shifting targets fit into the broader narrative and what to watch as the story develops from here. Analyst Price Targets...

Here is how Paysign, Inc. (PAYS) and Sezzle Inc. (SEZL) have performed compared to their sector so far this year.

Paysign (PAYS) is well positioned to outperform the market, as it exhibits above-average growth in financials.

PaySign Inc (PAYS) raises full-year guidance amid robust demand, with adjusted EBITDA up 113% and a strong pipeline of new program launches.

Paysign (NASDAQ:PAYS) reported record second-quarter revenue, net income and adjusted EBITDA for 2026, driven primarily by continued expansion in its Patient Affordability business and improving utilization in its plasma donor compensation operations. Revenue rose 48.1% from a year earlier to $28.3